NCT04263090View on ClinicalTrials.gov

Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

June 29, 2020

Primary Completion Date

December 20, 2023

Study Completion Date

December 20, 2023

Conditions
Non-small Cell Lung CancerAdenocarcinomaStage IV
Interventions
DRUG

Rigosertib

Rigosertib will be dosed twice a day for 21 consecutive days, followed by 7 days off treatment (each cycle duration: 28 days). Rigosertib escalation will occur with three dose levels (dose D1: 280mg twice daily; dose D2: 560mg qAM, 280mg qPM; dose D3: 560mg twice daily).

DRUG

Nivolumab

Nivolumab will be dosed once ever 2 weeks (twice per 28-day cycle; standard fixed dose of 240mg).

Trial Locations (1)

10029

Icahn School of Medicine at Mount Sinai, New York

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Traws Pharma, Inc.

INDUSTRY

lead

Icahn School of Medicine at Mount Sinai

OTHER

NCT04263090 - Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment | Biotech Hunter | Biotech Hunter